1810-71-5

Basic information

• Product Name: 6-BROMO-2-CHLORO-QUINOLINE
• Synonyms: 6-BROMO-2-CHLORO-QUINOLINE;2-Chloro-6-bromoquinoline;4,4'',4''-TRIIODOTRIPHENYLAMINE;Quinoline, 6-bromo-2-chloro-;6-broMo-2-chloro-;6-Bromo-2-chloro-1-azanaphthalene
• CAS NO: 1810-71-5
• Molecular Formula: C₉H₅BrClN
• Molecular Weight: 242.5
• EINECS: 1312995-182-4
• Product Categories: Aromatics Compounds;CHIRAL CHEMICALS;Aromatics;Heterocycles
• Mol File: 1810-71-5.mol
• Article Data: 25

Chemical Properties

• Melting Point: 148-150℃
• Boiling Point: 325.7°Cat760mmHg
• Flash Point: 150.8°C
• Appearance: /
• Density: 1.673g/cm³
• Vapor Pressure: 0.000429mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Soluble in Chloroform and Methanol
• PKA: -0.48±0.43(Predicted)
• CAS DataBase Reference: 6-BROMO-2-CHLORO-QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-CHLORO-QUINOLINE(1810-71-5)
• EPA Substance Registry System: 6-BROMO-2-CHLORO-QUINOLINE(1810-71-5)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• Hazardous Substances Data: 1810-71-5(Hazardous Substances Data)

Usage

Chemical Properties

White Crystalline Solid

Uses

It is used as a pharmaceutical intermediate.

InChI:InChI=1/C9H5BrClN/c10-7-2-3-8-6(5-7)1-4-9(11)12-8/h1-5H

Upstream product

• 5332-25-2 6-bromoquinoline 
• 1810-66-8 6-bromoquinoline-2-ol 
• 6563-11-7 6-bromoquinoline-N-oxide 
• 54934-81-5 N-(4-bromophenyl)prop-2-enamide 
• 106-40-1 4-bromo-aniline 
• 553-03-7 3,4-dihydro-2(1H)-quinolone 
• 71205-21-5 methyl (E)-3-(2-amino-5-bromophenyl)prop-2-enoate 
• 66416-72-6 4-bromo-2-iodoaniline 
• 3279-90-1 6-bromo-3,4-dihydro-1H-quinolin-2-one 
• 1810-66-8 6-bromo-2-quinolone 
• 327058-51-5 N-(4-bromophenyl)-(E)-3-ethoxyacrylamide 

Downstream Products

• 99455-05-7 2-methoxy-6-bromoquinoline 
• 1308869-78-4 6-o-tolylquinolin-2-amine 
• 1321991-85-8 6-(2-chlorophenyl)quinolin-2-amine 
• 1321991-86-9 6-(3-chlorophenyl)quinolin-2-amine 
• 1321991-87-0 6-(4-chlorophenyl)quinolin-2-amine 
• 1321991-88-1 6-cyclohexylquinolin-2-amine 
• 1350886-70-2 N-tert-butyl-6-cyclohexylquinolin-2-amine 
• 300811-62-5 2-(benzyloxy)-6-bromoquinoline 
• 78060-54-5 2-chloroquinoline-6-carbonitrile 
• 1366131-69-2 6-bromo-N-[4-(4-morpholinyl)phenyl]-2-quinolinamine 
• 1319194-22-3 (2-(2-amino-3-morpholinoquinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 
• 1319196-64-9 (2-(2-(4-methoxybenzylamino)-3-morpholinoquinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 
• 1319196-63-8 N-(4-methoxybenzyl)-3-morpholino-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-2-amine 
• 1319194-49-4 (2-(2-amino-3-(tetrahydro-2H-pyran-4-yl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 

Relevant articles and documents

Aminoquinoline-rhodium(II) conjugates as src-family SH3 ligands

High-affinity, selective ligands are sought for a variety of biomolecules but are particularly difficult to generate in the protein-protein interaction space. Rhodium(II) conjugates provide a structure-based approach to improved affinity and specificity f

Enantioselective Intermolecular [2 + 2] Photocycloaddition Reactions of 2(1H)-Quinolones Induced by Visible Light Irradiation

In the presence of a chiral thioxanthone catalyst (10 mol %) the title compounds underwent a clean intermolecular [2 + 2] photocycloaddition with electron-deficient olefins at λ = 419 nm. The reactions not only proceeded with excellent regio- and diastereoselectivity but also delivered the respective cyclobutane products with significant enantiomeric excess (up to 95% ee). Key to the success of the reactions is a two-point hydrogen bonding between quinolone and catalyst enabling efficient energy transfer and high enantioface differentiation. Preliminary work indicated that solar irradiation can be used for this process and that the substrate scope can be further expanded to isoquinolones.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.